Acellular vs whole cell whooping cough vaccines
Evidence SummariesLevel of Evidence = B
Multi-component acellular pertussis vaccines appear to be effective, and show less adverse effects than whole-cell pertussis vaccines for the primary series as well as for booster doses.
A Cochrane review 1 included 6 efficacy trials with a total of 46,283 participants and 52 safety trials with a total of 136,541 participants. Meta-analysis was not possible. The efficacy of multi-component (≥ 3) vaccines varied from 84% to 85% in preventing typical whooping cough, and from 71% to 78% in preventing mild pertussis disease. In contrast, the efficacy of one- and two-component vaccines varied from 59% to 75% against typical whooping cough, and from 13% to 54% against mild pertussis disease.
Multi-component acellular vaccines are more effective than low-efficacy whole-cell vaccines, but may be less effective than the highest-efficacy whole-cell vaccines. Most systemic and local adverse events were significantly less common with acellular than with whole-cell pertussis vaccines for the primary series as well as for the booster dose.
Comment: The quality of evidence is downgraded by inconsistency (heterogeneity in interventions and variability in results across studies).
1. Zhang L, Prietsch SO, Axelsson I et al. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev 2014;(9):CD001478. [PMID:25228233]
Copyright © 2017 Duodecim Medical Publications Limited.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.